Table 1:
Ongoing clinical trials investigating ICB in combination with AT for cancer treatments.
| Trial ID | Phase | Immunotherapy | Anti-angiogenic therapy | Disease |
|---|---|---|---|---|
| NCT02982694 | II | Atezolizumab | Bevacizumab | Advanced CRC |
| NCT03074513 | II | Atezolizumab | Bevacizumab | Several solid tumors |
| NCT02724878 | II | Atezolizumab | Bevacizumab | Advanced non-clear-cell RCC |
| NCT02921269 | II | Atezolizumab | Bevacizumab | Cervical cancer |
| NCT02997228 | III | Atezolizumab | Bevacizumab | CRC |
| NCT01984242 | II | Atezolizumab | Bevacizumab | Advanced RCC |
| NCT02420821 | III | Atezolizumab | Bevacizumab | Advanced RCC |
| NCT03133390 | II | Atezolizumab | Bevacizumab | Metastatic urothelial carcinoma |
| NCT02659384 | II | Atezolizumab | Bevacizumab | Ovarian cancer |
| NCT01688206 | I | Atezolizumab | Vanucizumab | Epithelial ovarian, fallopian tube or primary peritoneal cancer |
| NCT03170960 | I/II | Atezolizumab | Cabozantinib | Several solid tumors |
| NCT02493751 | I | Avelumab | Axitinib | Advanced RCC |
| NCT02684006 | III | Avelumab | Axitinib | Advanced RCC |
| NCT02572687 | I | Durvalumab | Ramucirumab | Several solid tumors |
| NCT02336165 | II | Durvalumab | Bevacizumab | GBM |
| NCT02496208 | I | Ipilimumab + nivolumab | Cabozantinib | Metastatic genitourinary cancer |
| NCT00790010 | I | Ipilimumab | Bevacizumab | Melanoma |
| NCT01950390 | II | Ipilimumab | Bevacizumab | Melanoma |
| NCT02210117 | I | Nivolumab, ipilimumab | Bevacizumab | RCC |
| NCT02873962 | II | Nivolumab | Bevacizumab | Relapsed ovarian, fallopian tube or peritoneal cancer |
| NCT02999295 | I/II | Nivolumab | Ramucirumab | Gastric cancer |
| NCT02576509 | III | Nivolumab | Sorafenib | Advanced HCC |
| NCT03172754 | I/II | Nivolumab | Axitinib | Advanced RCC |
| NCT02681549 | II | Pembrolizumab | Bevacizumab | Melanoma or NSCLC brain metastasis |
| NCT02337491 | II | Pembrolizumab | Bevacizumab | GBM |
| NCT02348008 | I/II | Pembrolizumab | Bevacizumab | Clear cell RCC |
| NCT02853318 | II | Pembrolizumab | Bevacizumab | Recurrent ovarian, fallopian tube, or primary peritoneal cancer |
| NCT02856425 | I | Pembrolizumab | Nintedanib | Several solid tumors |
| NCT02133742 | I | Pembrolizumab | Axitinib | Metastatic RCC |
| NCT02853331 | III | Pembrolizumab | Axitinib | Metastatic RCC |
| NCT02636725 | II | Pembrolizumab | Axitinib | Sarcoma |
| NCT02443324 | I | Pembrolizumab | Ramucirumab | Several solid tumors |
| NCT02014636 | I/II | Pembrolizumab | Pazopanib | Advanced RCC |
| NCT02298959 | I | Pembrolizumab | Aflibercept | Advanced tumors |
| NCT02501096 | I/II | Pembrolizumab | Lenvatinib | Several solid tumors |
| NCT03006887 | I | Pembrolizumab | Lenvatinib | Several solid tumors |
| NCT02811861 | III | Pembrolizumab | Lenvatinib | Advanced RCC |
| NCT02722954 | I | Pembrolizumab | Demcizumab | Metastatic solid tumors |
| NCT03603756 | II | SHR-1210 | Apatinib | Esophageal squamous cell carcinoma |
| NCT02039674 | I/II | Pembrolizumab | Bevacizumab | NSCLC |
| NCT03424005 | I/II | Atezolizumab | Bevacizumab | TNBC |
| NCT03555149 | I/II | Atezolizumab | Bevacizumab | Metastatic CRC |
| NCT03280563 | I/II | Atezolizumab | Bevacizumab | Breast neoplasms |
| NCT03414983 | II/III | Nivolumab | Bevacizumab | Metastatic CRC |
| NCT03193190 | I/II | Atezolizumab | Bevacizumab | Pancreatic adenocarcinoma |
| NCT03424005 | I/II | Atezolizumab | Bevacizumab | TNBC |
| NCT03175432 | II | Atezolizumab | Bevacizumab | Melanoma and other malignant neoplasms of skin |
CRC, colorectal cancer; RCC, renal cell carcinoma; GBM, glioblastoma; NSCLC, non-small cell lung cancer; TNBC, triple negative breast cancer.